SML2287

Applied Filters:

Keyword:'SML2287'

Showing 1-12 of 12 results for "SML2287" within Papers

Antifungal Activity of a Medical-Grade Honey Formulation against Candida auris.

Theun de Groot et al.

Journal of fungi (Basel, Switzerland), 7(1) (2021-01-17)

Candida auris is a pathogenic yeast causing outbreaks in intensive care units with high mortality rates. The treatment of C. auris colonization is challenging due to high resistance rates. A potential alternative antifungal treatment is medical-grade honey. In this study

Candida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia.

Laura Judith Marcos-Zambrano et al.

Antimicrobial agents and chemotherapy, 61(7) (2017-04-26)

The objectives of our study were to describe the characteristics of patients with Candida guilliermondii candidemia and to perform an in-depth microbiological characterization of isolates and compare them with those of patients with C. albicans candidemia. We described the risk

Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi.

Galina I Lepesheva et al.

The Journal of biological chemistry, 285(33), 25582-25590 (2010-06-10)

Trypanosoma cruzi causes Chagas disease (American trypanosomiasis), which threatens the lives of millions of people and remains incurable in its chronic stage. The antifungal drug posaconazole that blocks sterol biosynthesis in the parasite is the only compound entering clinical trials

Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.

Chiung-Kuang Chen et al.

PLoS neglected tropical diseases, 4(4), e651-e651 (2010-04-14)

Chagas Disease is the leading cause of heart failure in Latin America. Current drug therapy is limited by issues of both efficacy and severe side effects. Trypansoma cruzi, the protozoan agent of Chagas Disease, is closely related to two other

Colonisation and Transmission Dynamics of Candida auris among Chronic Respiratory Diseases Patients Hospitalised in a Chest Hospital, Delhi, India: A Comparative Analysis of Whole Genome Sequencing and Microsatellite Typing.

Anamika Yadav et al.

Journal of fungi (Basel, Switzerland), 7(2) (2021-02-04)

Candida auris is a nosocomial pathogen responsible for an expanding global public health threat. This ascomycete yeast has been frequently isolated from hospital environments, representing a significant reservoir for transmission in healthcare settings. Here, we investigated the relationships among C.

The use of posaconazole against Chagas disease.

Israel Molina et al.

Current opinion in infectious diseases, 28(5), 397-407 (2015-07-24)

The current therapeutic scenario against Chagas disease has been recently updated with the use of the triazoles in clinical trials and several experimental assays (in-vitro and in-vivo models) which are bringing novel and promising evidence for the treatment of Chagas

Posaconazole: a broad-spectrum triazole antifungal.

Harrys A Torres et al.

The Lancet. Infectious diseases, 5(12), 775-785 (2005-11-29)

Posaconazale is a new triazole drug being investigated in phase III clinical trials for the treatment and prevention of invasive fungal infections. In-vitro and in-vivo studies showed that posaconazole has broad-spectrum activity against most Candida species, Cryptococcus neoformans, Aspergillus species

Multiple unbiased approaches identify oxidosqualene cyclase as the molecular target of a promising anti-leishmanial.

Luciana S Paradela et al.

Cell chemical biology, 28(5), 711-721 (2021-03-11)

Phenotypic screening identified a benzothiophene compound with activity against Leishmania donovani, the causative agent of visceral leishmaniasis. Using multiple orthogonal approaches, oxidosqualene cyclase (OSC), a key enzyme of sterol biosynthesis, was identified as the target of this racemic compound and

Pharmacokinetic/pharmacodynamic profile of posaconazole.

Yanjun Li et al.

Clinical pharmacokinetics, 49(6), 379-396 (2010-05-21)

Posaconazole is a recently approved lipophilic triazole antifungal agent that exhibits potent and broad-spectrum antifungal activity in vitro and in vivo against most Candida spp., Cryptococcus neoformans, Aspergillus spp., many Zygomycetes, endemic fungi and dermatophytes. It has been documented that

Combining Colistin and Fluconazole Synergistically Increases Fungal Membrane Permeability and Antifungal Cidality.

Maayan Bibi et al.

ACS infectious diseases, 7(2), 377-389 (2021-01-21)

The increasing emergence of drug-resistant fungal pathogens, together with the limited number of available antifungal drugs, presents serious clinical challenges to treating systemic, life-threatening infections. Repurposing existing drugs to augment the antifungal activity of well-tolerated antifungals is a promising antifungal

Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

Eleftheria Mavridou et al.

Antimicrobial agents and chemotherapy, 54(2), 860-865 (2009-11-18)

The in vivo efficacy of posaconazole against 4 clinical Aspergillus fumigatus isolates with posaconazole MICs ranging from 0.03 to 16 mg/liter, as determined by CLSI method M38A, was assessed in a nonneutropenic murine model of disseminated aspergillosis. The underlying resistance

The Environmental Spread of Aspergillus terreus in Tyrol, Austria.

Anna-Maria Dietl et al.

Microorganisms, 9(3) (2021-04-04)

Fungal infections due to Aspergillus species have become a major cause of morbidity and mortality among immunocompromised patients. At the Medical University of Innsbruck, A. terreus and related species are the second most common causative agents of aspergillosis. In this

Page 1 of 1